
Artificial Heart Market Share
Artificial Heart Market Research Report Information by Type (Heart-Lung Machine, Mechanical Heart, Total Artificial Hearts, Ventricular Assist Devices (VADs)), End User (Hospitals & Clinics, Specialty Centers) and Region (Americas, Europe, Asia-Pacific, Middle East Africa) - Forecast till 2035

Market Summary
The Global Artificial Heart Market is projected to grow from 5 USD Billion in 2024 to 7.47 USD Billion by 2032.
Key Market Trends & Highlights
Artificial Heart Key Trends and Highlights
- The market is expected to experience a compound annual growth rate (CAGR) of 3.71% from 2025 to 2032.
- By 2035, the market valuation is anticipated to reach 7.47 USD Billion, reflecting a steady increase.
- In 2024, the market is valued at 5 USD Billion, indicating a robust foundation for future growth.
- Growing adoption of artificial hearts due to advancements in medical technology is a major market driver.
Market Size & Forecast
2024 Market Size | 5 (USD Billion) |
2035 Market Size | 7.47 (USD Billion) |
CAGR (2025-2035) | 3.71% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
SynCardia Systems, CryoLife, LLC, ABIOMED, CARMAT, Abbott, Cleveland Heart Inc., Thoratec Corporation
Market Trends
Drivers- the high increase in market demand of the artificial heart is due to the highly increased cardiovascular disorder among the population along with the increase in the aging population suffering from final stage heart failure. People engaging themselves in smoking along with reimbursement policies so implemented drives up the artificial heart valve market rate and its market value. People developing a high risk of heart complications increase the market growth of artificial heart.
Opportunities- medical device manufacturer is the lucrative opportunity that helps in driving up market growth. Some of the market drivers are an adaptation of new healthcare technology along with taking government initiatives to increase the opportunities of the market. Increased unavailability of favorable insurance policies widens up the opportunities for expanding the market growth of artificial heart.
Challenges- prevalence of HVD globally and regionally and certain regulatory approvals is the challenging factor towards the market growth.
Cumulative growth- the presence of high market value of high USD and high CAGR projects at a high rate covering large market share.
Restraints- strict rules so imposed by the government and the regulatory scenario so imposed as per the FDA policies are the factors that act as a restraining factor affecting the growth of the market. High costs of artificial heart valves along with the high treatment facilities and the regulations so imposed spoils up the market growth.
The ongoing advancements in biocompatible materials and miniaturization technologies are poised to enhance the efficacy and accessibility of artificial hearts, potentially transforming cardiac care for patients worldwide.
U.S. National Institutes of Health
Artificial Heart Market Market Drivers
Rising Prevalence of Cardiovascular Diseases
The increasing incidence of cardiovascular diseases globally is a primary driver for the Global Artificial Heart Market Industry. As heart-related ailments continue to escalate, the demand for advanced cardiac solutions, including artificial hearts, is likely to rise. In 2024, the market is projected to reach 5 USD Billion, reflecting the urgent need for innovative treatments. This trend is expected to persist as the World Health Organization indicates that cardiovascular diseases remain the leading cause of death worldwide. Consequently, healthcare systems are compelled to invest in artificial heart technologies to address this growing health crisis.
Market Segment Insights
Artificial Heart Type Insights
globally and regionally, the Artificial Heart Market has been classified into type and end-user. As per the type, the market is classified into the heart-lung machine and mechanical heart. The mechanical heart is further classified into total artificial hearts and ventricular assist devices.
The mechanical heart part projects at a high CAGR value during the market forecast period which contributes much more to the rise in market demand. Based on the end-users, the heart valve market is divided into hospitals and clinics and some healthcare centers, and many more.
Globally, the types of artificial heart valves expand to the region of America, Europe, Asia Pacific, some of the Middle East, and African regions. The Artificial Heart Market also expands to the regions of North America and some of Latin America areas where their region of North America includes the region of the United States and Canada.
The market expanded to the European region and is divided into Western Europe and Eastern Europe. The Western European region includes some of the areas of Germany, France, Italian areas, the United Kingdom, Spain, and other regions of Western Europe.
The market in the Asia Pacific market is divided into Japan, China, India, the South Korean region, Australia, and the rest of the Asia Pacific region.
Artificial Heart Technology Insights
due to advancement in technology advanced heart surgeries were used. It led to the invention of different types of artificial heart valves which functioned uniquely. Technology arouses awareness about the diagnosis facilities and the treatments. Technology led to the introduction of an innovative new artificial heart of low costs. The artificial heart cost and the cost of the artificial heart valve were not that huge.
Get more detailed insights about Artificial Heart Market Research Report - Forecast till 2032
Regional Insights
Key Companies in the Artificial Heart Market market include





Industry Developments
- Q2 2024: SynCardia Announces FDA Approval for Next-Generation Total Artificial Heart SynCardia Systems received FDA approval for its next-generation Total Artificial Heart, designed to improve patient outcomes and device durability. The approval marks a significant milestone for the company and expands treatment options for patients with end-stage heart failure.
- Q1 2024: Carmat Receives CE Mark Extension for Aeson Artificial Heart Carmat announced that it has received an extension of its CE Mark for the Aeson artificial heart, allowing continued commercial sales and use in European markets. The extension supports ongoing adoption of the device for patients with advanced heart failure.
- Q2 2024: Carmat Resumes Aeson Artificial Heart Production After Manufacturing Suspension Carmat resumed production of its Aeson artificial heart following a temporary suspension due to quality control issues. The company implemented corrective actions and received regulatory clearance to restart manufacturing and distribution.
- Q2 2024: SynCardia Systems Appoints New CEO to Drive Global Expansion SynCardia Systems announced the appointment of a new Chief Executive Officer, aiming to accelerate the company's global expansion and commercialization of its artificial heart technologies.
- Q1 2024: Carmat Raises €30 Million to Fund Artificial Heart Commercialization Carmat completed a €30 million funding round to support the commercialization and scale-up of its Aeson artificial heart in Europe and other markets.
- Q2 2024: Carmat Signs Distribution Agreement for Aeson Artificial Heart in Italy Carmat entered into a distribution agreement with a leading Italian medical device distributor to expand the availability of the Aeson artificial heart in Italy.
- Q1 2024: FDA Grants Breakthrough Device Designation to BiVACOR Total Artificial Heart The FDA granted Breakthrough Device Designation to BiVACOR's Total Artificial Heart, recognizing its potential to provide more effective treatment for patients with severe heart failure.
- Q2 2024: BiVACOR Announces First Human Implantation of Total Artificial Heart in U.S. Clinical Trial BiVACOR announced the successful first human implantation of its Total Artificial Heart as part of a U.S. clinical trial, marking a major milestone in the development of next-generation artificial heart technology.
- Q2 2024: Carmat Opens New Manufacturing Facility for Aeson Artificial Heart Carmat inaugurated a new manufacturing facility dedicated to the production of its Aeson artificial heart, aiming to increase capacity and meet growing demand in Europe.
- Q1 2024: SynCardia Systems Expands Distribution Network in Asia-Pacific SynCardia Systems announced the expansion of its distribution network in the Asia-Pacific region, partnering with local medical device companies to increase access to its Total Artificial Heart.
- Q2 2024: Carmat Signs Strategic Partnership with Leading U.S. Cardiac Center Carmat entered into a strategic partnership with a major U.S. cardiac center to advance clinical research and adoption of the Aeson artificial heart in the United States.
- Q1 2024: BiVACOR Secures $22 Million in Series B Funding to Advance Artificial Heart Development BiVACOR raised $22 million in Series B funding to accelerate the development and clinical testing of its Total Artificial Heart, supporting ongoing trials and regulatory submissions.
Future Outlook
Artificial Heart Market Future Outlook
The Global Artificial Heart Market is projected to grow at a 3.71% CAGR from 2024 to 2032, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.
New opportunities lie in:
- Develop innovative biocompatible materials for enhanced heart longevity.
- Expand telemedicine solutions for remote monitoring of artificial heart patients.
- Invest in partnerships with hospitals for integrated care pathways and patient education.
By 2035, the market is expected to exhibit robust growth, reflecting advancements and increased adoption of artificial heart technologies.
Market Segmentation
REPORT OVERVIEW
- {"Q2 2024: SynCardia Announces FDA Approval for Next-Generation Total Artificial Heart"=>[]}
- {"Q1 2024: Carmat Receives CE Mark Extension for Aeson Artificial Heart"=>[]}
- {"Q2 2024: Carmat Resumes Aeson Artificial Heart Production After Manufacturing Suspension"=>[]}
- {"Q2 2024: SynCardia Systems Appoints New CEO to Drive Global Expansion"=>[]}
- {"Q1 2024: Carmat Raises €30 Million to Fund Artificial Heart Commercialization"=>[]}
- {"Q2 2024: Carmat Signs Distribution Agreement for Aeson Artificial Heart in Italy"=>[]}
- {"Q1 2024: FDA Grants Breakthrough Device Designation to BiVACOR Total Artificial Heart"=>[]}
- {"Q2 2024: BiVACOR Announces First Human Implantation of Total Artificial Heart in U.S. Clinical Trial"=>[]}
- {"Q2 2024: Carmat Opens New Manufacturing Facility for Aeson Artificial Heart"=>[]}
- {"Q1 2024: SynCardia Systems Expands Distribution Network in Asia-Pacific"=>[]}
- {"Q2 2024: Carmat Signs Strategic Partnership with Leading U.S. Cardiac Center"=>[]}
- {"Q1 2024: BiVACOR Secures $22 Million in Series B Funding to Advance Artificial Heart Development"=>[]}
Report Scope
Report Attribute/Metric | Details |
Market Size | USD 5 Billion |
CAGR | 14.30% |
Base Year | 2023 |
Forecast Period | 2023-2032 |
Historical Data | 2020 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, and End user |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | SynCardia Systems, LLC, BiVACOR Inc., CARMAT, Cleveland Heart, Inc., ABIOMED, CryoLife, Inc., Abbott, and Thoratec Corporation |
Key Market Opportunities | Medical device manufacturer |
Key Market Drivers | · Adaptation of healthcare technology · Government initiatives to increase the healthcare quality · Availability of favorable insurance policies |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
What was the valuation in 2030?
The valuation was USD 4.98 billion.
What is the predicted CAGR for the Artificial Heart Market for the forecast period (2022-2030)?
The predicted CAGR would be 14.3%.
What could slow down market growth?
The high cost of the procedure and regulations regarding the process can slow down the growth.
Which type to lead the market?
The mechanical heart segment has the chance to record a higher CAGR.
Which region would take charge of the artificial heart market?
The Americas market would dominate the global field.
-
Table of Contents:
-
Chapter 1. Report Prologue
-
Chapter 2. Market Introduction
- Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
-
Chapter 3. Research Methodology
- Introduction
- Primary Research
- Secondary Research
- Market Size Estimation
-
Chapter 4. Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Detection Technique Trends & Assessment
-
Chapter 5. Market Factor Analysis
-
Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
-
Porter’s Five Forces Analysis
-
Chapter 6. Global Artificial Heart Market, by Type
- Introduction
- Heart-Lung Machine
-
Market Estimates & Forecast, by Region, 2020-2027
-
Market Estimates & Forecast, by Country, 2020-2027
- Mechanical Heart
-
Market Estimates & Forecast, by Region, 2020-2027
- Total Artificial Hearts
-
Market Estimates & Forecast, by Country, 2020-2027
- Ventricular Assist Devices (VADs)
-
Market Estimates & Forecast, by Country, 2020-2027
-
Chapter 7. Global Artificial Heart Market, by End User
- Introduction
- Hospitals & Clinics
-
Market Estimates & Forecast, by Region, 2020-2027
-
Market Estimates & Forecast, by Country, 2020-2027
- Specialty Centers
-
Market Estimates & Forecast, by Region, 2020-2027
- Others
-
Chapter 8. Global Artificial Heart Market, by Region
- Introduction
-
Americas
- North America
- Latin America
-
Europe
- Western Europe
- Eastern Europe
-
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa
- Middle East
- Africa
-
Chapter 9 Company Landscape
- Introduction
- Market Share Analysis
- Key Development & Strategies
-
Chapter 10. Company Profiles
-
SynCardia Systems, LLC
- Company Overview
- Treatment Overview
- Financials Overview
- Key Developments
- SWOT Analysis
-
BiVACOR Inc.
- Company Overview
- Treatment Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
CARMAT
- Company Overview
- Treatment Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
Cleveland Heart, Inc.
- Company Overview
- Treatment Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
ABIOMED
- Company Overview
- Treatment Overview
- Financial overview
- Key Developments
- SWOT Analysis
-
CryoLife, Inc.
- Company Overview
- Treatment Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Abbott
- Company Overview
- Treatment Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Thoratec Corporation
- Company Overview
- Treatment Overview
- Financials
- Key Developments
- SWOT Analysis
-
SynCardia Systems, LLC
-
Chapter 11 MRFR Conclusion
-
Key Findings
- From CEO’s Viewpoint
- Unmet Needs of the Market
- Key Companies to Watch
- Predictions for the Artificial Heart Industry
-
Key Findings
-
Chapter 12. Appendix
-
List of Tables and Figures
- LIST OF TABLES
- Table 1 Global Artificial Heart Market Synopsis, 2020-2027
- Table 2 Global Artificial Heart Market Estimates and Forecast, 2020-2027 (USD Million)
- Table 3 Global Artificial Heart Market, by Region, 2020-2027 (USD Million)
- Table 4 Global Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 5 Global Artificial Heart Market, by End-User, 2020-2027 (USD Million)
- Table 8 North America: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 9 North America: Artificial Heart Market, by End User, 2020-2027 (USD Million)
- Table 12 US: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 13 US: Artificial Heart Market, by End User, 2020-2027 (USD Million)
- Table 16 Canada: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 17 Canada: Artificial Heart Market, by End User, 2020-2027 (USD Million)
- Table 20 Latin America: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 21 Latin America: Artificial Heart Market, by End User, 2020– 2023 (USD Million)
- Table 24 Europe: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 25 Europe: Artificial Heart Market, by End User, 2020-2027 (USD Million)
- Table 28 Western Europe: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 29 Western Europe: Artificial Heart Market, by End User, 2020– 2023 (USD Million)
- Table 32 Eastern Europe: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 33 Eastern Europe: Artificial Heart Market, by End User, 2020– 2023 (USD Million)
- Table 36 Asia-Pacific: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 37 Asia-Pacific: Artificial Heart Market, by End User, 2020-2027 (USD Million)
- Table 40 Middle East & Africa: Artificial Heart Market, by Type, 2020-2027 (USD Million)
- Table 41 Middle East & Africa: Artificial Heart Market, by End User, 2020-2027 (USD Million) LIST OF FIGURES
- Figure 1 Research Process
- Figure 2 Segmentation for Global Artificial Heart Market
- Figure 3 Segmentation Market Dynamics for Global Artificial Heart Market
- Figure 4 Global Artificial Heart Market Share, by Type, 2020
- Figure 5 Global Artificial Heart Market Share, by End User, 2020
- Figure 7 Global Artificial Heart Market Share, by End User, 2020
- Figure 8 Global Artificial Heart Market Share, by Region, 2020
- Figure 9 North America: Artificial Heart Market Share, by Country, 2020
- Figure 10 Europe: Artificial Heart Market Share, by Country, 2020
- Figure 11 Asia-Pacific: Artificial Heart Market Share, by Country, 2020
- Figure 12 Middle East & Africa: Artificial Heart Market Share, by Country, 201
- Figure 13 Global Artificial Heart Market: Company Share Analysis, 2020 (%)
- Figure 14 SynCardia Systems, LLC: Key Financials
- Figure 15 SynCardia Systems, LLC.: Segmental Revenue
- Figure 16 SynCardia Systems, LLC: Geographical Revenue
- Figure 17 BiVACOR Inc.: Key Financials
- Figure 18 BiVACOR Inc.: Segmental Revenue
- Figure 19 BiVACOR Inc.: Geographical Revenue
- Figure 20 CARMAT: Key Financials
- Figure 21 CARMAT: Segmental Revenue
- Figure 22 CARMAT: Geographical Revenue
- Figure 23 ABIOMED: Key Financials
- Figure 24 ABIOMED: Segmental Revenue
- Figure 25 ABIOMED.: Geographical Revenue
Artificial Heart Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment